Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Compression ⢠Rising Leverage ⢠Strong Liquidity TMDX maintains strong liquidity and resilient gross margins, but investors should monitor sharp quarterly margin compression, rising leverage, weaker cash generation, and negative retained earnings.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Weak momentum Support Level: $82â$84 Resistance Level: $88â$90 TMDX remains in a modest last-month downtrend below $88â$90 resistance, with $82â$84 support critical for limiting further downside.
Sentiment & News
Key News Insights: ⢠Revenue Growth ⢠Margin Pressure ⢠Legal Scrutiny TransMedics shows strong growth momentum and investor interest, but margin pressure, CFO transition, and legal investigations raise execution and risk concerns.
AI Summary
TMDX remains a compelling growth story, but investors should now demand proof that its logistics and international investments can convert 20%+ revenue growth into recovering margins and free cash flow before adding exposure, as rising leverage and a heavier cost base raise the downside if utilization lags.
Description
TransMedics Group is a commercial-stage medical technology company that develops and commercializes portable systems for perfusion, preservation and monitoring of donor organs to support transplantation in the U.S. and abroad. Its Organ Care System recreates near-physiologic conditions ex vivo and includes device variants for lungs, hearts and livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 25 | Jan 1 | TMDX | TransMedics Group, Inc. | TransMedics exhibits strong fundamentals with 32% Q3 revenue growth, expanding profitability, international launch imminent, and key clinical trials underway. Though near-term technical momentum is bearish, medium-term growth prospects and pipeline catalysts make it a watch-for-entry hot idea. | Closed | -4.2% |
| Sep 8 | Sep 15 | TMDX | TransMedics Group, Inc. | TransMedics delivered robust Q2 revenue (+38% YoY), raised 2025 guidance, received an FDA conditional approval for a key trial (Aug 2025), and shows strong technical momentum with clear near-term catalysts, although ongoing litigation and valuation levels advise cautious position sizing. | Closed | +8.3% |